George Sgouros, PhD
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. The success and recent FDA approval of an alpha-emitter–based radiopharmaceutical for prostate cancer patients has led to renewed interest in the use of alpha-particle emitters in humans for targeted therapy. Because of the nature of alpha-particle radiation, this new treatment modality is fundamentally different from existing therapies. This monograph reviews pioneering and current studies related to targeted alpha-particle-emitter therapy and provides guidance and recommendations for human dosimetry.
Non-Member Price: $49.00
Member Price: $35.00
Please note: Shipping is free within the U.S.; please expect delivery within 15 business days.